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ABSTRACT 
Objective: To investigate the relation between orthostatic hypotension (OH) and 
posture-mediated cognitive impairment in persons with Parkinson's disease (PD) 
without dementia.  
Methods: There were 55 participants: 37 non-demented individuals with idiopathic PD, 
including 18 with OH (PDOH), and 19 without (PDWOH), and18 control participants 
(C). All participants completed neuropsychological tests in the supine and in the 
upright tilted position. Blood pressure was assessed in each posture using a 
standardized oscillometric cuff at the right brachial artery.  
Results: The two PD groups performed similarly while supine, with a profile notable for 
executive dysfunction consisting of deficits in sustained attention, response inhibition, 
and semantic verbal fluency, as well as reduced verbal memory encoding and 
retention. When upright, these deficits were exacerbated and broadened to include 
additional cognitive functions in the PDOH group: deficits in phonemic verbal fluency, 
psychomotor speed, and both basic and complex aspects of auditory working 
memory. When group-specific supine scores were used as baseline anchors, both PD 
groups showed cognitive changes following tilt, though the PDOH group had a wider 
range of deficits in the executive functioning and memory domains and was the only 
group to show significant changes in visuospatial skills. 
Conclusions:  Cognitive deficits in idiopathic PD have been widely reported, though 
assessments are typically performed in the supine position. While both PD groups had 
supine deficits that aligned with prior studies and clinical findings, we demonstrated 
that those with PD and orthostatic hypotension had transient, posture-mediated 
changes in excess of those found in PD without autonomic failure. These observed 
changes suggest an acute, reversible effect, and as orthostatic hypotension is a 
significant comorbid factor in PD, an independent target for clinical intervention. 
Further understanding of the effects of autonomic failure on cognition in other 
disorders is desirable, particularly in the context of neuroimaging studies and clinical 
assessments where data are collected only in the supine or seated positions. 
Identification of a distinct neuropsychological profile in PD with autonomic failure also 
has implications for functional activities of daily living and overall quality of life. 
 
 
GLOSSARY 
BAI=Beck Anxiety Index; BDI-II=Beck Depression Inventory (II); CERAD=Consortium 
to Establish a Registry for Alzheimer’s Disease; DBP=diastolic blood pressure; 
DRT=dopamine replacement therapy; GDS=Geriatric Depression Scale; HR=heart 
rate; HY=Hoehn and Yahr motor symptom stage scale; MMSE=Mini-Mental State 
Examination;  C=normal control; OH=orthostatic hypotension; PD=Parkinson’s 
Disease; PDWOH=Parkinson’s Disease without orthostatic hypotension; 
PDOH=Parkinson’s Disease with orthostatic hypotension; SBP=systolic blood 
pressure; WTAR=Wechsler Test of Adult Reading  
Over the past two decades, there has been an increase in attention to non-motor 
symptoms of Parkinson’s disease (PD). Of these, orthostatic hypotension (OH) is 
among the most commonly reported, with prevalence as high as 53%.1 Consensus 
criteria for diagnosing OH include a reduction in systolic blood pressure (SBP) of at 
least 20 mmHg or in diastolic blood pressure (DBP) of at least 10 mmHg within the 
first three minutes after a change in posture from supine to either the standing or 
upright-tilted position.2 Symptoms include lightheadedness, fatigue, neck pain, 
presyncope, and syncope.3, 4 However, asymptomatic OH common and is itself a risk 
factor for mortality and cardiovascular disease.5 In PD, the causes of OH are multiple, 
and can include both central and peripheral degeneration.6 Dopamine replacement 
therapies have been implicated as well, though these effects are likely disease-
modulated and not directly caused by the drugs themselves.7 
Orthostatic hypotension is associated with cognitive impairment. Even when 
controlling for SBP, elderly individuals with OH score lower on bedside cognitive 
screening measures relative to matched controls.8 In younger adults without comorbid 
neurological disorders and when tested in the seated position, those with OH show 
relative deficits in verbal memory and sustained attention, both of which are predictors 
of subsequent cognitive decline that is greater than would be expected in the context 
of normal aging.9 
Idiopathic PD is itself associated with cognitive deficits. Historically, these were 
thought to be limited to psychomotor/information processing speeds and caused by 
disease-specific subcortical pathologies.10 However, deficits across executive 
functions, including metacognitive and  regulatory aspects of goal-directed behavior 
have also been shown, even in cases without significant motor slowing.11 Executive 
dysfunction in PD is caused by an alteration of connectivity between prefrontal and 
striatal regions, whose networks contain dense dopaminergic and cholinergic 
projections.12-15 Thus, an updated model of cognitive decline in PD is now 
appropriately characterized as a disconnection syndrome.16 
While both OH and PD are linked to cognitive decrements, few studies have 
considered the independent contribution of each towards specific impairments. Of 
those that have included OH as a factor influencing neuropsychological test 
performance, those with OH have scored lower on screening measures and have 
showed modest relative deficits in sustained attention, visuospatial processing and 
visual episodic memory relative to those with normal hemodynamics.17-19 Importantly, 
cognitive testing in these studies was conducted only in the seated position, yet 
deficits OH-related deficits emerged nonetheless. 
The mechanism by which OH worsens cognition in PD is not fully elucidated. 
Structural imaging studies with cognitive variables have thus far failed to support the 
notion that such vulnerability is the result of anoxic changes to white matter integrity or 
of overall vascular burden.18 An alternative explanation suggests that disease-specific 
deficits are exacerbated during periods of sympathetic stress due to autoregulatory 
failure in those regions which are already compromised. In Lewy body disease, 
selective hypoperfusion is generally seen within the temporal and occipital lobes 
independent of autonomic dysfunction and visuospatial deficits are indeed 
pathognomonic. In those with concomitant OH, however, postural change is followed 
by further hypoperfusion but only in posterior regions, and those that show the 
greatest relative change have more significant deficits in visuospatial cognition. This 
pattern of selective hypoperfusion in response to sympathetic stress would suggest 
that cognition may also vary across supine and upright positions. To our knowledge, 
however, no studies have utilized this format to determine the effects of OH on 
cognition in PD or other synucleinopathies.  
We hypothesized that cognition is transiently impaired during OH in PD. We also 
hypothesized that persons with PD and OH would have fixed cognitive deficits that are 
more severe than those with PD without OH. We used standard autonomic 
assessment tools to determine whether the presence of OH would be associated with 
immediate effects on cognition as well as impairment independent of posture when 
compared to persons with PD without OH. 
 
METHODS The study was approved by the Boston University and Beth Israel 
Deaconess Medical Center Institutional Review Boards. All participants provided 
written informed consent. 
Study Sample. Fifty-five non-demented individuals participated in the study: 18 
patients with both PD and neurogenic OH (PDOH), 19 normotensive PD patients 
(PDWOH), and 18 control participants (C). OH was defined as a sustained reduction 
in systolic blood pressure (SBP) of at least 20 mmHg and/or a reduction in diastolic 
blood pressure (DBP) of at least 10 mmHg during the first three minutes of standing or 
head-up tilt on a sixty-degree tilt table.2 All groups were matched on age, education, 
and male:female ratio. Control participants were not excluded if maintained on anti-
hypertensive medications, so long as they were normotensive at the time of testing 
and had no evidence of OH. The Mini-Mental State Examination was used as a 
general cognitive screening with a cutoff of 27 for C and 25 for PD. The cutoff for PD 
was lower to account for disease-specific (i.e. motor) errors that are not associated 
with dementia.20 Participants also received the Beck Depression Inventory (BDI-II),21 
the Geriatric Depression Scale (GDS),22 and the Beck Anxiety Inventory (BAI).23 For 
those with PD, side of symptom onset, Hoehn and Yahr motor stage, and treatment 
history were obtained. All met clinical criteria for mild to moderate idiopathic PD 
(Hoehn and Yahr stages I-III). Dopaminergic therapies were converted to levodopa 
equivalent dosages (LED).24 
Autonomic assessment. Assessment of autonomic functioning was completed in 
accordance with standardized clinical protocols. Participants were instructed to eat a 
light breakfast two hours prior to testing. Upon arrival, they were allowed a 20-minute 
rest in the supine position to attain psychological and physiological equilibration. RR 
interval, beat-to-beat blood pressure (Finometer, FMS, Amsterdam, the Netherlands), 
and oscillometric blood pressure (Dinamap, Critikon Company, Tampa, FL) were 
measured for five minutes in the supine position, followed by 15 minutes in the 60-
degree tilted position. Exclusion criteria included any subjective symptoms associated 
with orthostasis (lightheadedness, dizziness, etc.) that were rated as severe (>8 on a 
10 point Likert scale), significant tachycardia (>150 BPM) or SBP in the range 
associated with presyncope/syncope. Of the 55 participants who met eligibility, none 
were excluded using these criteria. During the testing session, arterial pressure was 
measured for three minutes at one-minute intervals while supine. A battery of 
neuropsychological tests was then administered. Participants were then tilted to 60 
degrees at a rate of 6 degrees/sec. Arterial pressures were again measured at one-
minute intervals for three minutes prior to the start of the second session of testing. 
Following test completion, participants were returned to the supine position. Once 
systolic pressure returned to within 10 mmHg of baseline, this sequence (supine-tilt) 
was repeated for sessions three and four. Throughout the assessment, participants 
reported subjective symptoms using the same 10-point Likert scale introduced during 
the initial screening. To control for the effects of subjective symptoms on cognitive 
performance, a score of 8 or higher was used to determine data exclusion; no 
participants met this criterion. 
Cognitive Assessment. The Wechsler Test of Adult Reading (WTAR) was 
administered prior to testing as a measure of premorbid verbal intelligence.25 For each 
session, the order of test administration was counterbalanced, and validated 
alternate-forms or split-halves were used in each subsequent session to maintain 
internal consistency. All tests with visual stimuli and/or motor components were 
adapted for projection on a large screen at approximately 53-degree visual angle with 
responses given orally.26 Specific tests included: 
Attention/Executive Functioning. A Stroop test was used as a measure of 
sustained attention and response inhibition;27 The Digit Span Test to assess basic 
auditory attention and working memory; the Arithmetic test to assess working memory 
and logical reasoning;28 the Verbal Fluency Test (phonemic and semantic) to assess 
retrieval processes;29 and the Symbol Search Test to assess visual scanning and 
psychomotor speeds.28 
Memory.The CERAD VLT was used to assess verbal memory. Variables analyzed 
included scores on the first recall trial, the total encoded words across trials (Total 
Score), learning slope, and delayed recall.30 
Visuospatial Functioning. The Hemifield Lines Test was used to measure right/left 
biases in two conditions. For this measure, a line presented in one hemifield changes 
incrementally in size until the participant perceives it to be the same size as a line of 
constant length in the opposite hemifield.31 The Line Bisection Test was used to 
determine egocentric reference points, and the Visual Dependence Test was used to 
assessed line orientation and angle judgment.31 
Statistical Analysis. Statistical analysis was performed using SPSS v17.0 (SPSS 
Inc.). Analyses of variance with Tukey post-hoc analysis were used to examine group 
differences on clinical measures except for median Hoehn&Yahr score (chi square 
analysis). Group differences in baseline supine conditions were analyzed using one-
way analysis of variance with Tukey post-hoc analysis. Paired-samples t-tests were 
used to detect differences from supine to tilted performance on within-group cognitive 
performance, and change in z-score performance from supine to tilted positions was 
used as an index of relative impairment. Alpha for cognitive measures was 0.01 to 
correct for multiple comparisons. 
 
RESULTS Study Sample. None of the participants met criteria for dementia. There 
were no differences across groups with regard to age, male:female distribution, or 
premorbid verbal IQ. PD groups were similar with regard to left/right side of symptom 
onset, disease stage/duration and LED. (Table 1). PDOH patients were more likely to 
be on anti-hypotensive medications than the C and PDWOH groups. C were more 
likely to be on anti-hypertensive medications than PDOH but not PDWOH. Both 
PDWOH and PDOH scored higher on the BDI-II than did C (p<0.05, both groups) and 
PDOH scored higher than PDWOH (p<0.05). PDOH scored higher on the GDS than 
did C (p<0.05), while differences between PD groups were not significant. On the BAI, 
both PD groups scored higher than C(p<0.05) but were similar to each other. 
Hemodynamic Measures. There were no significant group differences in baseline 
SBP, DBP, or heart rate. Supine hypertension (SPB > 135 mmHg and/or DBP > 100) 
was found in 6 of 19 PDOH, 5 of 18 PDWOH, and 4 of 18 C (Table 2).  
Cognitive Measures. Supine. Compared to C, both PD groups showed impaired 
cognition (Table 3). PDWOH performed more poorly than C on Semantic Fluency and 
on both Stroop conditions. They also displayed reduced memory encoding and 
delayed recall. There were no differences on any visuospatial measures. PDOH was 
impaired relative to C on several executive tasks including Digit Span Backwards, 
Symbol Search, both fluency tests, and the Stroop test. They were also impaired on 
all memory sub-measures, but not on any visuospatial measures. There were no 
differences between PD groups on any cognitive measure. 
Upright Tilt. Compared to C, PDWOH was impaired on several executive measures 
and had poorer memory encoding (Table 4). PDOH participants, however, performed 
more poorly than C on nearly all executive measures, including several that did not 
elicit differences between C and PDWOH. PDOH also had a worse memory encoding 
than PDWOH and showed a trend towards weaker recall after a delay. There were no 
significant differences between groups on any measure of visuospatial functioning, 
though PDOH showed a trend towards relative impairment on Visual Dependence. 
Changes in Performance. Within-group, following tilt. C had no within-group 
changes when supine and upright performances were compared. PDWOH 
demonstrated deficits when upright relative to supine on Symbol Search and two 
CERAD subtests (Learning and Delayed Recall, p<0.001). PDOH showed posturally-
mediated impairment on nearly all measures of cognition, including Arithmetic 
(p<0.001), Symbol Search (p<0.001), both fluency conditions (p<0.01), memory 
encoding and retention (p<0.01), and Line Bisection (p<.01). Trends were observed 
for Digit Span Backward (p=0.043), learning slope (p=0.038), and both conditions of 
Hemifield Lines (Hemifield-left, p=0.028; Hemifield-right, 0.041).  
Across-group, following tilt. The change in group-specific z-score following tilt was 
used as an index of relative performance (i.e., to control for baseline differences that 
may have skewed the effect of postural change) (Figure 1).There were no significant 
differences in the effect of postural change on cognition between the C and PDWOH 
groups. By contrast, PDOH showed a greater posture-mediated impairment than C on 
several tests, including Arithmetic, Symbol Search, Semantic Fluency, Digit Span 
Backward (with a trend on Digit Span Forward p=.05), the Stroop test, memory 
encoding (p<0.01) and Visual Dependence (p=.01). Compared to PDWOH, PDOH 
showed a significantly greater effect of postural change on Symbol Search (p<0.01) 
CERAD Total Score (p<0.01) and Visual Dependence (p<0.01). 
 
DISCUSSION Ours is the first study to assess cross-sectional and within-group, 
posture-specific neuropsychological performance to determine the effects of OH on 
cognition in PD. We found broader executive dysfunction and visuospatial impairments 
in PDOH as part of an overall exacerbated deficit profile when cognition was assessed 
in the upright position, with a subsequent return to baseline performance following 
supination. This transient change was not observed in PDWOH or C participants and 
would thus imply a direct effect of autonomic failure. 
 
Cognitive deficits in PD are, at least in part, the result of central neurodegeneration. 
This presents a challenge when determining the relative contribution of other 
comorbidities. Reports of cognitive deficits in pure autonomic failure, where 
degeneration is limited to the peripheral autonomic nervous system, suggest that 
hemodynamics do indeed play a role. Cognitive deficits have also been observed in 
autonomic autoimmune ganglionopathy, a rare disorder where nicotinic acetylcholine 
receptor antibodies disrupt transmission across autonomic ganglia, leading to 
autonomic failure. Following plasma exchange and titer reduction, OH resolves and 
cognition improves. These antibodies appear to not be acting centrally, thus the 
associated cognitive impairment is more likely related to either a global reduction in 
peripheral sympathetic activation or, in the setting of normal large-vessel cerebral 
blood flow, the attenuation of peripheral neurovascular regulation in a regionally-
specific response to cognitive demand.32, 33 
 
As expected, PD groups displayed frontostriatal and visuospatial cognitive deficits 
relative to C. This pattern is observed in as many as 55% of all individuals with PD and 
is the result functional disconnectivity. Specifically, the basal ganglia and its dense 
dopaminergic and cholinergic projections to multiple cortical regions as well as the 
thalamus are selectively affected in a progressive and disease-specific process.34 It is 
this central degeneration that causes global alterations of neurotransmission and the 
emergence of numerous motor and non-motor signs that associated with the disease.  
It is notable that we found no meaningful differences across PD groups while supine, 
as this contrasts with at least one previous report.35 However, the prevalence of supine 
hypertension in the OH group was significantly lower in the present study. By ensuring 
normal supine pressures across groups, we reduced the likelihood of comorbid white-
matter angiopathy, a known and independent risk factor for cognitive impairment.36-38  
PD groups were also matched across measures of disease duration, motor symptom 
severity, and LED. There is considerable support, therefore, that these transient 
decrements following postural change are independently related to a failure of cerebral 
autoregulation during orthostatic stress.  
 
As the overwhelming majority of clinical neuropsychological tests, if not all, are 
administered in the seated position, it would be reasonable to modify assessment 
methodology in PD to include testing in a variety of postures. In this study, only those 
with mild-to-moderate symptoms of OH (and many who were asymptomatic) were 
included, though cognitive impairments emerged nonetheless. Clinicians should 
therefore consider both autonomic and functional cognitive assessments in all persons 
with PD regardless of subjective concerns brought forth by the patient. Furthermore, as 
delayed OH is common in patients with PD and other alpha-synucleinopathies, 
clinicians should also be mindful of this manifestation for those individuals who show 
normal hemodynamics within the first three minutes of standing.  
 
A multiphasic cognitive profile would be instructive for providers and would reveal 
otherwise unrecognized targets for intervention. For instance, impairments in verbal 
fluency, already noted in PD, could make it increasingly difficult to communicate 
effectively. This would not be appreciated in a private office setting, but perhaps when 
conducting affairs in public spaces, where sitting is not an option. Impairments in visual 
processing could lead to problems in the marketplace, where searching for wanted 
items among a varied array of goods would be a particular challenge. Similarly, 
difficulties with judging line orientation would likely increase the risk of falls, and as 
postural instability is already a core feature of PD, a provider might not consider such 
cognitive impairment as contributive. Working memory problems might lead to 
difficulties with tracking conversations or when counting change, further complicating 
interactions about town and possibly eliciting symptoms of social anxiety. There are 
also implications for functional neuroimaging studies, in which data are collected 
without consideration of postural hemodynamics. If the cause of cognitive change in 
OH is related to alterations in regional cerebral blood flow or task-specific metabolic 
activity as we suggest, prior studies may have failed to fully demonstrate the 
neurophysiological underpinnings of cognitive decline, particularly in diseases where 
OH is a common finding. Finally, as delayed OH is common in patients with PD and 
other alpha-synucleinopathies, clinicians should be mindful of this manifestation for 
those individuals who show normal hemodynamics within the first three minutes of 
standing.  
 
It is difficult to fully rule out all potential confounds when assessing cognition, 
particularly when utilizing repeat-assessments and in disease states where multiple 
comorbidities are common. With regard to possible iatrogenic effects of dopamine 
agonists, which have been shown to produce or worsen OH and cause cognitive 
deficits, we controlled for levodopa equivalent dosages and found no associated 
differences in OH severity or cognitive performance.39,40 We also addressed potential 
confounds that would otherwise affected interpretation of our neuropsychological test 
findings. As noted, we excluded those with salient symptoms during tilt, and while 
reliance on the subjective report of such symptoms has inherent flaws, we are 
confident that the cognitive changes as observed in this study were not symptom-
driven. With regard to the potential threats to validity following repeated 
neuropsychological assessment, several methodological safeguards were put in place. 
We counterbalanced the order of test administration, used alternate forms when 
available, and randomized split-halves when no alternate forms existed. Perhaps more 
importantly, had any order or practice effects emerged they would have served to 
mitigate our hypothesized differences across groups, as all participants were first 
tested the supine position. 
  
Table 1 - Demographic and clinical information characteristics 
  
C 
(n=18) 
 
PDWOH 
(n=19) 
 
PDOH 
(n=18) 
    
Men : Women (#) 9:9 11:8 11:7 
Age (years) 62.9 ± 7.6 65.6 ± 9.5 64.3 ± 6.5 
Education (years) 17.9 ± 1.3 17.5 ±1.4 16.9 ±1.6 
Disease stage (HY score) N/A 2 (1-3) 2(1-3) 
Disease duration (years) N/A 5.7 ± 2.0 6.7 ± 2.3 
On DRT (#)  N/A 17  17  
LED (mg) N/A 591 ± 329 513 ± 303 
On Anti-hypertensive (#) 6c 4 1a 
On Anti-hypotensive (#) 0c 0c 4a 
WTAR (raw score) 46.9 ± 1.3 46.1 ± 3.2 45.7± 2.2 
MMSE (raw score) 28.9 ±1.1c 28.4 ± 1.1c 27.1 ± 1.4a 
 
Abbreviations: HY=Hoehn&Yahr, DRT=dopamine replacement therapy, LED=levodopa equivalent dose, 
WTAR=Wechsler Test of Adult Reading, MMSE=Mini-Mental State Exam. 
 
Reported as means ±SD, except HY score, which is reported as median (range). 
 
aSignificant at p<0.05 vs. C 
b Significant at p<0.05 vs. PDWOH 
c Significant at p<0.05 vs. PDOH 
Table 2 - Hemodynamic information 
  
C 
(n=18) 
 
PDWOH 
(n=19) 
 
PDOH 
(n=18) 
Supine hemodynamics    
 SBP (mmHg) 125.5 ± 11.7 125.2 ± 16.3 130.9 ± 14.6 
 DBP (mmHg) 72.6 ± 8.4 74.6 ± 16.5 78.0 ± 8.9 
 HR (bpm) 66.6 ± 8.7 67.4 ± 9.0 66.0 ± 9.4 
Change following tilt    
 SBP (mmHg) -2.3 ± 10.9c -4.6 ± 6.9c -30.4 ± 7.9a,b 
 DBP (mmHg) 2.6 ± 7.0c 1.2 ± 8.9c -12.2 ± 8.7a,b 
 HR (bpm)  7.9 ± 4.6 8.5 ± 5.9 8.6 ± 5.7 
 
Abbreviations: SBP=systolic blood pressure, DBP=diastolic blood pressure, HR=heart rate (beats per minute). 
 
Change refers to subsequent rise (+) or fall (-) in blood pressure after postural change from supine to upright tilt, 
reported as means ± SD. 
 
aSignificant at p<0.05 vs. C 
b Significant at p<0.05 vs. PDWOH 
c Significant at p<0.05 vs. PDOH  
Table 3 - Across-group comparison of performance on cognitive measures while supine  
  
C 
(n=18) 
 
PDWOH 
(n=19) 
 
PDOH 
(n=18) 
Digit Span  Forward (total score) 11.6 ± 2.5 10.9 ± 1.7 10.9 ± 1.7 
Digit Span Backward (total score) 8.9 ± 1.8c 7.9 ± 1.7 7.2 ± 1.5a 
Arithmetic (split half total score) 6.2 ± 1.2 6.1 ± 0.8 5.9 ± 1.2 
Symbol Search (total score) 33.8 ± 6.7c 28.9 ± 5.4 26.2 ± 4.9a 
Phonemic Fluency (words/min) 21.1 ± 4.2 17.1 ± 3.6 17.1 ± 4.4 
Semantic Fluency (words/min) 25.5 ± 3.5b,c 20.2 ± 5.1a 20.0 ± 5.2a 
Stroop Color (total correct) 261 ± 35b,c 213 ± 41a 218 ±37a 
Stroop Color-word (total correct) 120 ± 25b 90  ± 20a 98 ± 24 
    
CERAD Trial 1 (words recalled) 6.1 ± 1.5c 5.2 ± 1.2 4.5 ± 1.2a 
CERAD Trial 2 (words recalled) 8.3 ± 1.2b,c 6.4 ± 1.5a 6.1 ± 0.8a 
CERAD Trial 3 (words recalled) 8.9 ± 1.1b,c 7.1 ± 1.0a 7.2 ± 1.3a 
CERAD Total Score (T1+T2+T3) 23.3 ± 3.2b,c 18.6 ± 3.5a 17.8 ± 2.8a 
CERAD Total Learning (T3 -T1) 2.8 ± 1.5b 1.9 ± 0.7a,c 2.7 ± 1.1a,b 
CERAD Recall (words recalled) 7.3 ± 1.6b,c 4.7 ± 1.6a 4.6 ± 2.4a 
    
Hemi - L (deviation from equal size) 0.75 ± 0.7 0.64 ±0.6 0.97 ± 0.8 
Hemi - R (deviation from equal size) 0.79 ± 0.7 1.18 ±1.9 1.18 ± 1.1 
Line Bisection (deviation from midline) 0.57 ± 0.5 0.77 ±0.5 0.95 ± 0.7 
Visual Dependence (deviation from horizontal) 0.46 ± 0.5 0.72 ± 0.5 0.53 ± 0.4 
 
Abbreviations: CERAD=Consortium to Establish a Registry for Alzheimer's Disease verbal learning test, 
Hemi=Hemifield Lines test. 
 
Scores are reported as raw values ± standard deviations for each individual measure and within 
neuropsychological domains. 
 
aSignificant at p<0.01 vs. C 
b Significant at p<0.01 vs. PDWOH 
c Significant at p<0.01 vs. PDOH  
Table 4 - Across-group comparison of performance on cognitive measures under upright tilt 
  
C 
(n=18) 
 
PDWOH 
(n=19) 
 
PDOH 
(n=18) 
Digit Span  Forward (total score) 12.1 ± 2.7c 10.8 ± 1.6 9.9 ± 1.6a 
Digit Span Backward (total score) 8.1 ± 1.6c 7.7 ± 1.3c 5.7 ± 1.1a,b 
Arithmetic (split half total score) 6.2 ± 1.3c 5.5 ± 1.5c 4.2 ± 1.0a,b 
Symbol Search (total score) 31.6 ± 5.5b,c 27.2 ± 5.6c 21.9 ± 3.7a,b 
Phonemic Fluency (words/min) 20.2 ± 4.3b,c 16.1 ± 3.5a,c 12.8 ± 3.5a 
Semantic Fluency (words/min) 23.3 ± 4.4b,c 18.2 ± 4.2a 14.9 ± 4.7a 
Stroop Color (total correct) 261 ± 34b,c 194 ± 46a 195 ± 40a 
Stroop Color-word (total correct) 127 ± 16b,c 94 ± 18a 86 ± 19.2a 
    
CERAD Trial 1 (words recalled) 5.9 ± 1.3c 5.1 ± 1.1c 3.8 ± 0.6a,b 
CERAD Trial 2 (words recalled) 7.8 ± 0.9b,c 6.1 ± 1.1a,c 4.8 ± 0.9a,b 
CERAD Trial 3 (words recalled) 8.7 ± 1.3b,c 7.0 ± 1.3a,c 5.8 ± 1.2a 
CERAD Total Score (T1+T2+T3) 22.4 ± 2.4b,c 18.1 ± 3.1a,c 14.3 ± 2.3a,b 
CERAD Total Learning (T3 -T1) 2.8 ± 1.9 1.9 ± 1.0 2.0 ± 1.2 
CERAD Recall (words recalled) 6.2 ± 1.9b,c 4.3 ± 1.7a 2.9 ± 2.9a 
    
Hemi - L (deviation from equal size) 0.89 ± 0.7 1.20  ± 1.0 1.48 ± 1.3 
Hemi - R (deviation from equal size) 1.11 ± 0.8 1.78  ± 1.5 1.67 ± 1.3 
Line Bisection (deviation from midline) 0.68 ± 0.6 1.16  ± 0.8 0.84 ± 0.6 
Visual Dependence (deviation from horizontal) 0.57 ± 0.5c 0.71 ± 0.6c 1.35 ± 1.0a,b 
 
Abbreviations: CERAD=Consortium to Establish a Registry for Alzheimer's Disease verbal learning test, 
Hemi=Hemifield lines test 
 
Scores are reported as raw values ± standard deviations for each individual measure and within 
neuropsychological domains. 
 
aSignificant at p<0.01 vs. C 
b Significant at p<0.01 vs. PDWOH 
c Significant at p<0.01 vs. PDOH 
  
Figure 1 - Cognitive performance reflected as group-specific (ex. C, PDWOH, PDOH) change from baseline 
followingtilt. 
 
 
Prior to analysis of change, all raw scores on cognitive measures were converted to group-specific z scores, 
where the mean and standard deviation in the supine position of each specific group (C, PDWOH, PDOH) were 
used to determine relative within-group performance while under upright tilt. Values reported are for within-group z 
score change for each measure. Error bars represent standard error.  
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